

Bridge House  
The Point  
Lions Way  
Sleaford  
NG34 8GG

Tel FOI team: 01246 514965

E-mail FOI team: [agcsu.foi.lincs@nhs.net](mailto:agcsu.foi.lincs@nhs.net)

Web: [www.lincolnshireccg.nhs.uk](http://www.lincolnshireccg.nhs.uk)

31<sup>st</sup> July 2020

## FREEDOM OF INFORMATION – DECISION NOTICE

Dear Requester

**FOI Reference Number: 001868**

I refer to your email of 15<sup>th</sup> June 2020 requesting information in respect of shared care agreements/arrangements established between the CCG, secondary care and local primary care services for the treatment of Psoriasis and Psoriatic Arthritis.

I can confirm on behalf of NHS Lincolnshire CCG and in accordance with S.1 (1) of the Freedom of Information Act 2000 (FOIA) that we do hold some of the information that you have requested. A response to each element of your request is detailed below.

Established on 1 April 2020, the CCG is a newly formed public sector organisation, though we hold information pertaining to NHS Lincolnshire East, NHS Lincolnshire West, NHS South Lincolnshire and NHS South West Lincolnshire CCGs which date back to April 2013. Where appropriate for the request we have indicated below which of the above previous organisations the information relates to.

### REQUEST AND RESPONSE

1. Has a shared care agreement/arrangement been established between the CCG, secondary care and local primary care services (e.g. general practitioners) for the treatment of Psoriasis and Psoriatic Arthritis? **Psoriasis:** Y/N **Psoriatic Arthritis:** Y/N

#### RESPONSE:

**Psoriasis:** N **Psoriatic Arthritis:** N - The CCG does not have specific shared care covering treatment of either of these conditions. The CCG has shared care in place covering the use of azathioprine, ciclosporin and methotrexate for management of dermatological conditions which includes psoriasis. In the case of psoriatic arthritis the CCG has individual shared care for methotrexate and leflunomide which cover use drugs for a variety of rheumatoid conditions both shared care include use for management of this condition.

2. If you answered 'Yes' to Q1, what are the names and/or roles of the signatories of the shared care agreement?

#### RESPONSE:

- All shared care is approved at a meeting of Lincolnshire Prescribing and Clinical Effectiveness Forum (PACEF) and date of meeting is noted on the shared care.

- Dermatology shared care authors 2 x Consultant Dermatologists from United Lincolnshire Hospitals, Medical Director from Lincolnshire LMC, Support Services Pharmacist from Optum Medicine Management team which provides Medicine Management Services to Lincolnshire CCG.
- Rheumatology shared care authors Consultant Rheumatologist from United Lincolnshire Hospitals, Nurse Specialist –Rheumatology from United Lincolnshire Hospitals, Support Services Pharmacist from Optum Medicine Management team which provides Medicine Management Services to Lincolnshire CCG.

3. If you answered 'Yes' to Q1, which of the following medicines can be prescribed within the shared care agreement?

Psoriasis			Psoriatic Arthritis		
Apremilast	Methotrexate	Dimethyl Fumarate	Apremilast	Methotrexate	Tofacitinib
	<b>RESPONSE:</b> Yes		<b>RESPONSE:</b> Yes		

4. How many consultant-led **community-based** Dermatology or Rheumatology services has your CCG commissioned that treat Psoriasis or Psoriatic Arthritis?

**RESPONSE:** One for Dermatology

5. Who/where are these services commissioned from?

**RESPONSE:** DMC Healthcare

6. Which of the following treatments can be prescribed by these services?

Treatment	Y/N
Methotrexate	N
Ciclosporin	N
PUVA	N
Apremilast (PDE4i)	N
Dimethyl Fumarate (Psoriasis)	N
Tofacitinib (Psoriatic Arthritis)	N
Biologics* (*See annex 1 for list of biologic therapies)	N

**RESPONSE:** None

7. How many GPwERs has your CCG commissioned for Dermatology, and Rheumatology? Please provide the geographical locations of these commissioned services.

	How many GPwERs has your CCG commissioned?	Please provide the geographic locations of these commissioned services
<b>Dermatology</b>	<b>RESPONSE:</b> 2	<b>RESPONSE:</b> Lincolnshire West locality
<b>Rheumatology</b>	<b>RESPONSE:</b> NIL	<b>RESPONSE:</b> All areas

8. Are digital services commissioned by the CCG for the management of Dermatology and Rheumatology?

If so, please specify the digital services provided? This may include tele dermatology services (various levels) and/or virtual clinics.

	<b>Dermatology</b>	<b>Rheumatology</b>
Are digital services commissioned by the CCG within Dermatology and Rheumatology in your area? (Y, N, N/A)	<b>RESPONSE:</b> Yes (in service specification to be implemented during contract term)	<b>RESPONSE:</b> Nil
Please specify the type and level of digital services provided?	<b>RESPONSE:</b> Virtual outpatient appointments commenced due to COVID	<b>RESPONSE:</b> Nil

**Annex 1 to original request**

adalimumab (Amgevita®, Humira®, Hyrimoz® or Imraldi®)
brodalumab (Siliq®)
certolizumab (Cimzia®)
etanercept (Benepali®)
golimumab (Simponi®)
guselkumab (Tremfya®)
infliximab (Remicade®)
ixekizumab (Taltz®)
risankizumab (Skyrizi®)
secukinumab (Cosentyx®)
tildrakizumab (Ilumya®)
ustekinumab (Stelara®)

I hope that this answers your queries with the information we currently hold, but if I can be of any further assistance please do not hesitate to contact me.

If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Arden & GEM Greater East Midlands Commissioning Support Unit  
FOI TEAM, Room 18  
Scarsdale Hospital  
Chesterfield  
S41 7PF

If you are not content with the outcome of your complaint, you may apply directly to the Information Commissioner for a decision. Generally, the ICO cannot make a decision unless you have exhausted the complaints procedure provided the CCG.

The Information Commissioner can be contacted at: telephone 0303 123 1113, email [casework@ico.org.uk](mailto:casework@ico.org.uk) and <https://ico.org.uk/global/contact-us/>

*Under the terms of the Open Government Licence, you may use and re-use the information provided within this response (not including logos or photographs), free of charge in any format or medium; unless identified as another party's copyright.*

<http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>

Yours faithfully

June Emptage  
Information Governance Officer

***On behalf of  
NHS Lincolnshire CCG***